Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma

뉴스 본문을 불러오고 있어요.

Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma | 웨이프 WAPE

Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma

기사 요약

관련 종목

댓글 —